PF-Organized Corticosteroid-Associated Heterogeneity in Sepsis
Key facts
- Who runs it
- Shanghai Zhongshan Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 2,693 people enrolled
- Started
- 5 Aug 2026
- Ended
- 27 Sept 2026
- Type of study
- Observational, 3 groups
- Treatments tested
- Systemic Corticosteroids
- Record updated
- 3 November 2026
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- ICU stays or eligible ICU records from the ICCA, MIMIC, or eICU databases
- Meets the database-specific operational definition of sepsis used in the study
- Has an ascertainable ICU mortality outcome or the corresponding harmonized database-specific mortality endpoint
- Has the relevant corticosteroid exposure and clinical data required for the corresponding analysis
Who cannot take part
- For the ICCA cohort, records with antimicrobial treatment patterns more consistent with postoperative prophylaxis than active infection
- ICU stays or records that do not meet the finalized database-specific sepsis definition
- For the ICCA cohort, ICU stays with a duration of 48 hours or less
- Records with unavailable or invalid mortality outcome information
- Records with missing exposure or other essential variables required for the corresponding analysis; Analysis-specific exclusions:
- Records without available PaO₂/FiO₂ measurements were excluded from analyses requiring P/F stratification, but were not necessarily excluded from the broader source cohort
- Records with missing model-specific covariates were excluded from the corresponding complete-case analyses only
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This retrospective multicohort observational study evaluates whether the PaO2/FiO2 ratio (P/F ratio) organizes heterogeneity in the association between early systemic corticosteroid exposure and mortality among critically ill patients with sepsis.
Read full original descriptionShow less
The study uses one internal critical-care cohort (ICCA) and two external critical-care databases (MIMIC and eICU). Analyses include internal discovery, broad external testing, reconstruction of external cohorts toward vasopressor-anchored shock-decision contexts, realized-exposure observational analyses, and strategy-level analyses using a simplified clone-censor-weighting framework (Lite-CCW).
The primary objective is to characterize whether corticosteroid-associated outcome patterns differ across P/F strata and whether similar directional patterns are observed across independent ICU datasets after decision-context reconstruction. The study is hypothesis-generating and does not assign corticosteroid treatment or define a clinical treatment-selection rule.
The 3 groups in the trial
- ICCA Cohort
Critically ill patients meeting the finalized ICCA sepsis phenotype. Realized systemic corticosteroid exposure was assessed within 0-72 hours after cohort time zero. The finalized manuscript-facing ICCA cohort included 2,693 ICU stays.
Treatment: Systemic Corticosteroids
- MIMIC Cohort
Patients represented in the broad MIMIC ICU cohort, with reconstructed main and shock-aligned subsets used for external decision-context analyses. Realized corticosteroid exposure was assessed within 0-24 hours after time zero.
Treatment: Systemic Corticosteroids
- eICU Cohort
Patients represented in the broad eICU critical-care cohort, with reconstructed main and shock-aligned subsets used for external decision-context analyses. Realized corticosteroid exposure was assessed within 0-24 hours after time zero.
Treatment: Systemic Corticosteroids
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Decision-Context-Aligned Multicohort Framework for PF-Organized Corticosteroid-Associated Heterogeneity in Sepsis
- Record updated
- 3 November 2026